David Fischer joined Charles River through the acquisition of BioFocus from Galapagos. He has since taken a leadership role on a number of early-stage drug discovery programs in rare and orphan disease indications, including cystic fibrosis, Huntington’s Disease, ALS, Usher III Syndrome, and DMD. He brings expertise in complex and primary cell-based assays, including iSPC and hESC stem cells models. David holds a degree in chemistry and a Ph.D. in molecular genetics. During six years of postdoctoral fellowships, he focused on neurodegenerative diseases, particularly Alzheimer’s and Huntington’s disease. Dr. Fischer has published over 50 patent applications and peer-reviewed papers.